ArticleThe oncologist2026

Pancreatic ductal adenocarcinoma with ITSN1-ALK fusion: sustained response to alectinib with 19-month progression-free survival.

Chaoxing Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.